Search results for " coagulation"

showing 10 items of 221 documents

Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study (RABAMES): six-month results of a prospective randomized clinical trial

2014

Purpose To compare standard-of-care grid laser photocoagulation versus intravitreal ranibizumab (IVR) versus a combination of both in the treatment of chronic (>3 months) macular oedema secondary to branch retinal vein occlusion. Methods Prospective, randomized, multicentre clinical trial. Thirty patients with a best-corrected visual acuity (BCVA) between 20/320 and 20/40 were randomized 1:1:1 to receive grid laser or three monthly injections of 0.5 mg IVR or both followed by 3 months of observation. Results Mean change from baseline BCVA at month 6 was +2 letters [laser; 0.04 logMAR, 95% confidence interval (−0.17; 0.25)], +17 letters [IVR; 0.34 (0.19; 0.5)] and +6 letters [combination; 0.…

AdultMaleVascular Endothelial Growth Factor Amedicine.medical_specialtyVisual acuitygenetic structuresVisual AcuityAngiogenesis InhibitorsAntibodies Monoclonal HumanizedMacular Edemalaw.invention03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRandomized controlled trialRecurrencelawRanibizumabOphthalmologyRetinal Vein OcclusionHumansMedicineProspective Studies030212 general & internal medicineMacular edemaAgedAged 80 and overLaser Coagulationbusiness.industryRetinalGeneral MedicineMiddle Agedmedicine.diseaseCombined Modality TherapyConfidence interval3. Good healthSurgeryClinical trialOphthalmologychemistryIntravitreal Injections030221 ophthalmology & optometryBranch retinal vein occlusionFemaleLasers SemiconductorRanibizumabmedicine.symptombusinessmedicine.drugActa Ophthalmologica
researchProduct

Prothrombotic State Induced by Middle-Distance Endurance Exercise in Middle-Aged Athletes

2018

AbstractSince the impact of possible prothrombotic factors on blood coagulation resulting from exercise remains elusive, this study investigated the acute effects of middle-distance endurance running on blood coagulation parameters in middle-aged athletes. The study population consisted of 33 male endurance runners who were engaged in a 21.1 km run under competitive conditions. Blood samples were collected before the run, immediately after the run, and 3 hours after run completion. Samples were assessed for activated partial thromboplastin time (APTT), prothrombin time (PT), fibrinogen, D-dimer, factor VIII (FVIII), von Willebrand factor antigen (VWF:Ag), endogenous thrombin potential (area…

AdultMalecongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyphysical activity030204 cardiovascular system & hematologyFibrinogenRunningblood coagulation03 medical and health sciences0302 clinical medicineVon Willebrand factorEndurance traininghemic and lymphatic diseasesInternal medicineABO blood group systemvon Willebrand FactormedicineHumansExerciseblood coagulation; hemostasis; physical activity; thrombin generation; Adult; Blood Coagulation; Exercise; Factor VIII; Fibrinogen; Humans; Male; Middle Aged; Partial Thromboplastin Time; Physical Endurance; Running; Thrombin; Thrombosis; von Willebrand Factor; AthletesProthrombin timeFactor VIIImedicine.diagnostic_testbiologyChemistryThrombinFibrinogenThrombosisHematologyMiddle Agedprothrombotic factors blood coagulation sportprothrombotic factorsEndocrinologyCoagulationAthletesthrombin generationHemostasishemostasisPhysical Endurancebiology.proteinPartial Thromboplastin TimeCardiology and Cardiovascular Medicinesportcirculatory and respiratory physiology030215 immunologyPartial thromboplastin timemedicine.drug
researchProduct

Role of factor V Leiden or G20210A prothrombin mutation in patients with symptomatic pulmonary embolism and deep vein thrombosis: a meta-analysis of …

2012

AdultMalemedicine.medical_specialtyAdolescentDeep veinRisk AssessmentGastroenterologyYoung AdultRisk FactorsInternal medicineOdds RatiomedicineFactor V LeidenHumansGenetic Predisposition to DiseaseIn patientChildBlood CoagulationAgedAged 80 and overVenous ThrombosisChi-Square DistributionProthrombin mutationbusiness.industryFactor VHematologyOdds ratioMiddle Agedmedicine.diseaseThrombosisSurgeryPulmonary embolismPhenotypemedicine.anatomical_structureMeta-analysisMutationFemaleProthrombinPulmonary Embolismbusiness
researchProduct

Subfascial Endoscopic Perforator Surgery With Tumescent Local Anesthesia

2002

background. Subfascial endoscopic perforator surgery (SEPS) has become an established procedure. objective. To evaluate SEPS with tumescent local anesthesia (TLA) using an single-port device originally designed for that purpose. methods. Patients selected for SEPS received subcutaneous infiltration of TLA into the medial aspect of the calf 20 minutes before surgery. Bipolar coagulation and dissection were used to treat incompetent perforators. results. Fifty-one patients with 67 legs of CEAP stages C3–C6 underwent SEPS with TLA. In 40 patients or 53 legs (79.1%) TLA alone allowed successful completion of the SEPS procedure. Five patients with 7 legs (10.4%) required additional intravenous a…

AdultMalemedicine.medical_specialtyConscious SedationSuccessful completionDermatologyVaricose UlcerPain controlmedicineHumansLocal anesthesiaIn patientAgedEndoscopesLegVascular diseasebusiness.industryEquipment DesignGeneral MedicineMiddle AgedIncompetent perforatorsmedicine.diseaseSurgerybody regionsTreatment OutcomeVenous InsufficiencyAnesthesiaFemaleSurgeryVenous diseasebusinessVascular Surgical ProceduresBipolar coagulationAnesthesia LocalDermatologic Surgery
researchProduct

Reduced recanalization rates of the great saphenous vein after endovenous laser treatment with increased energy dosing: Definition of a threshold for…

2006

Background Recent reports indicated a correlation between the amount of energy released during endovenous laser treatment (ELT) of the great saphenous vein (GSV) and the success and durability of the procedure. Our objective was to analyze the influence of increased energy dosing on immediate occlusion and recanalization rates after ELT of the GSV. Methods GSVs were treated with either 15 or 30 W of laser power by using a 940-nm diode laser with continuous fiber pullback and tumescent local anesthesia. Patients were followed up prospectively with duplex ultrasonography at day 1 and at 1, 3, 6, and 12 months. Results A total of 114 GSVs were treated with 15 W, and 149 GSVs were treated with …

AdultMalemedicine.medical_specialtyDuplex ultrasonographyTime FactorsAdolescentmedicine.medical_treatmentAngioscopyOcclusionmedicineHumansSaphenous VeinLocal anesthesiaProspective StudiesDosingVeinAgedAged 80 and overUltrasonography Doppler DuplexLaser Coagulationmedicine.diagnostic_testbusiness.industryGreat saphenous veinEndovenous laser treatmentMiddle AgedAngioscopySurgeryTreatment Outcomemedicine.anatomical_structureVenous InsufficiencyChronic DiseaseFemaleSurgeryCardiology and Cardiovascular MedicinebusinessFollow-Up StudiesJournal of Vascular Surgery
researchProduct

Safety of plasma-derived protein C for treating disseminated intravascular coagulation in adult patients with active cancer

2012

Cancer-related disseminated intravascular coagulation (DIC) is a life-threatening condition for which no effective treatment is currently available. Protein C (PC), a modulator of coagulation as well as the inflammatory system, has been successfully tested (in its activated recombinant form [a-rPC]) in sepsis-related coagulopathy, but with an increased risk for major bleeding. Plasma-derived PC (pd-PC) is more suitable than a-rPC in patients at high risk from bleeding due to its self-limiting process. We carried out a single-arm study evaluating the role of pd-PC in adult cancer patients with overt DIC. Over a period of 3 years, we treated 19 patients with overt DIC and a PC plasma concentr…

AdultMalemedicine.medical_specialtyGastroenterologySettore MED/15 - Malattie Del SangueNeoplasmsInternal medicineCoagulopathymedicineHumansBlood Coagulationdisseminated intravascular coagulationSurvival analysisAgedAged 80 and overDisseminated intravascular coagulationHematologic Testsbusiness.industryPlasma derivedAnticoagulantsCancerHematologyMiddle Agedmedicine.diseaseSurvival AnalysisThrombosisSurgeryCoagulationFemalebusinessProtein CProtein Cmedicine.drugAmerican Journal of Hematology
researchProduct

Endovenous treatment of the great saphenous vein using a 1,320 nm Nd:YAG laser causes fewer side effects than using a 940 nm diode laser.

2005

Limited data are available about treatment-related side effects with respect to laser wavelength in endovenous laser treatment (ELT) of the great saphenous vein (GSV).To compare the results and side effects of a 940 nm diode and a 1,320 nm neodymium:yttium-aluminum-garnet (Nd:YAG) laser.Three patient cohorts (A, B, and C) received ELT of the GSV using a 940 nm diode laser at 15 W (group A) or 30 W (group B) or using a 1,320 nm laser at 8 W (group C). In all cases, energy was administered continuously with constant pullback of the laser fiber under perivenous tumescent local anesthesia.The GSVs of group A (n = 113), group B (n = 136), and group C (n = 33) received ELT. An average linear endo…

AdultMalemedicine.medical_specialtyMaterials scienceAdolescentmedicine.medical_treatmentTreatment outcomechemistry.chemical_elementDermatologyNeodymiumlaw.inventionlawmedicineHumansSaphenous VeinDiodeAgedRetrospective StudiesAged 80 and overLaser Coagulationbusiness.industryGreat saphenous veinEndovenous laser treatmentGeneral MedicineMiddle AgedLaserSurgeryChronic diseaseTreatment OutcomechemistryVenous InsufficiencyNd:YAG laserChronic DiseaseSurgeryFemaleNuclear medicinebusinessDermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
researchProduct

Prevention of haemophilic arthropathy during childhood. May common orthopaedic management be extrapolated from patients without inhibitors to patient…

2008

We recommend prophylaxis in haemophilic children with an inhibitor as a way of preventing the musculoskeletal impairment that is likely to affect them. This approach has been used for children without inhibitors with excellent results. If prophylaxis is not feasible, we suggest that intensive on-demand treatment should be given. Two agents, recombinant activated FVII (rFVIIa) and activated prothrombin complex concentrates (aPCC), are currently used to control haemostasis either for prophylaxis or intensive on-demand treatment. As it is recombinant, rFVIIa would seem more appropriate to be employed in children. aPCC could be used in adults, or in the event of an unsatisfactory response to rF…

AdultMalemedicine.medical_specialtyPediatricsTime FactorsEvidence-based practiceAdolescentFactor VIIaHemophilia AHaemophiliaFactor IXYoung AdultHemarthrosismedicineOrthopaedic proceduresHumansPain ManagementOrthopedic ProceduresChildIntensive care medicinePhysical Therapy ModalitiesGenetics (clinical)Randomized Controlled Trials as TopicRetrospective StudiesHaemophilic arthropathySynovitisBlood Coagulation Factor InhibitorsCoagulantsbusiness.industryMusculoskeletal impairmentHematologyGeneral MedicinePerioperativemedicine.diseaseSkeletal maturityBlood Coagulation FactorsRecombinant ProteinsCartilageTreatment OutcomeChild PreschoolPractice Guidelines as TopicbusinessPROTHROMBIN COMPLEXHaemophilia : the official journal of the World Federation of Hemophilia
researchProduct

Thrombotic events in systemic lupus erythematosus. Its association with acquired and inherited thrombophilic defects.

2008

Systemic lupus erythematosus (SLE) is characterised by increased venous and arterial thrombotic risk. Although antiphospholipid antibodies (APAs) have been shown to be related with thrombotic tendency in these patients, in more than 40% of them, thrombosis occurs without the presence of such antibodies. We analysed the association of venous and arterial thrombotic events with acquired (anticardiolipin antibodies (ACAs) and lupus anticoagulant (LA)) and inherited (antithrombin (AT), protein C (PC), protein S (PS) deficiencies, factor V Leiden and the prothrombin G20210A mutation), thrombophilic risk factors in 86 SLE patients and 89 healthy controls. Patients showed a higher significant perc…

AdultMalemedicine.medical_specialtyPhysiologyGastroenterologyProtein SRisk FactorsPhysiology (medical)Internal medicinemedicineFactor V LeidenHumansLupus Erythematosus SystemicRisk factorLupus anticoagulantbiologybusiness.industryAntithrombinThrombosisHematologyBlood ProteinsMiddle Agedmedicine.diseaseThrombosisVenous thrombosisAntibodies AnticardiolipinLupus Coagulation InhibitorImmunologyMutationbiology.proteinFemaleCardiology and Cardiovascular MedicinebusinessProtein Cmedicine.drugClinical hemorheology and microcirculation
researchProduct

Retinal vascular occlusion and deficiencies in the protein C pathway.

1999

Abstract PURPOSE: To report abnormalities in the protein C pathway and other vascular occlusion risk factors in patients with retinal vascular occlusion. METHODS: In a study, we investigated 76 consecutive patients who had in-patient evaluation of venous or arterial retinal vascular occlusion. All patients underwent comprehensive tests for coagulation disorders including determinations of protein C, protein S, lupus anticoagulants, and resistance to activated protein C and were screened for vascular disease risk factors. Resistance to activated protein C was confirmed by a polymerase chain reaction method to detect the specific factor V R506Q mutation. For comparative purposes, we also scre…

AdultMalemedicine.medical_specialtyRetinal Artery OcclusionDeep veinVascular occlusionGastroenterologyProtein SProtein SCentral retinal vein occlusionRisk FactorsInternal medicineRetinal Vein OcclusionmedicinePrevalenceHumansProspective StudiesActivated Protein C ResistanceAgedRetinal Vascular OcclusionAged 80 and overbiologybusiness.industryFactor VFactor VProtein C DeficiencyMiddle Agedmedicine.diseaseThrombosisSurgeryOphthalmologymedicine.anatomical_structureLupus Coagulation InhibitorMutationbiology.proteinBranch retinal vein occlusionFemalemedicine.symptombusinessProtein CAmerican journal of ophthalmology
researchProduct